Back to top
Close
Steve Reitmeister

"Today, I Will Give You
5 Stocks Set to Double Absolutely Free"

Dear Zacks.com Visitor,

I invite you to download a free Special Report that names 5 tickers, each tabbed by a Zacks expert to gain +100% and more in the next 12 months.

One company announced a cancer breakthrough that scored a 79% increase in progression-free survival in Phase III testing. Another is set to gain steam from a $3.45 billion acquisition. Still another has room for price increases that could send margins through the roof. Don't miss these stocks with compelling gain potential.

Omnicell Inc: (OMCL)

(Market Close from NSDQ) As of Feb 26, 2015 03:59 PM ET

 Add to portfolio

 ZacksTrade Now

$35.34 USD

35.34
123,038

-0.10 (-0.28%)

Volume: 123,038

Zacks Rank : 4-Sell [?]       4  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 26.65%
2 Buy 18.84%
3 Hold 10.45%
4 Sell 4.76%
5 Strong Sell 2.56%
S&P 500 10.28%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The way to access to the Zacks Rank

Quote Overview

Stock Activity

Open 35.36
Day Low 35.02
Day High 35.64
52 Wk Low 25.00
52 Wk High 35.75
Avg. Volume 241,537
Market Cap 1.26 B
Dividend 0.00 ( 0.00%)
Beta 0.92

Key Earnings Data

Forward PE 35.98
PEG Ratio 2.04
Current Qtr Est 0.14
Current Yr Est 0.99
Most Accurate Est 0.14
Qtr Earnings ESP[?] 0.00%
Exp Earnings Date 5/7/15
Prior Year EPS 0.97
Exp EPS Growth 17.67%
Industry MEDICAL INFO SYSTEMS

Earnings ESP (Expected Surprise Prediction) is Zacks’ proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement.

Read more about this innovative method in the Zacks Earnings ESP Guide See all the top Earnings ESP Stocks.

Premium Research for OMCL

Zacks Rank [?] Rank Change Trend Sell 4
Zacks Industry Rank 160 / 265 (Bottom 40%)
Equity Research Report

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 26.65%
2 Buy 18.84%
3 Hold 10.45%
4 Sell 4.76%
5 Strong Sell 2.56%
S&P 500 10.28%

Zacks Rank Education - Learn more about the Zacks Rank

Zacks Rank Home - All Zacks Rank resources in one place

Zacks Premium - The only way to get access to the Zacks Rank

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Learn to Profit from the Zacks Rank

Zacks Recommendation has been removed. Learn more

Due to overwhelming customer feedback we have removed the Zacks Recommendation. Unfortunately, having two separate rating systems proved far too confusing to most investors. Going forward we will just focus on the Zacks Rank which has a longer and more impressive track record of outperformance. Even though the Zacks Rank is primarily used for stock trading in a 1-3 month time frame, it also can be very helpful for long term investors. To learn more about using the Zacks Rank for long term investing, click here.

Premium Research : Industry Analysis

Top Peers Symbol Zacks Rank
OMNICELL INC OMCL
ALLSCRIPTS HLTH MDRX
CERNER CORP CERN
ATHENAHEALTH IN ATHN
COLLABRX INC CLRX
FOUNDATION MED FMI
HMS HLDGS CP HMSY
MEDIDATA SOLUTN MDSO
MERGE HEALTHCAR MRGE
OMNICOMM SYSTEM OMCM

See all MEDICAL INFO SYSTEMS Peers>>